Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
- Conditions
- PainCancer
- Registration Number
- NCT00105287
- Lead Sponsor
- Cephalon
- Brief Summary
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- Documented diagnosis of a malignant solid tumor or hematological malignancy causing cancer related pain
- Currently taking around the clock opioid therapy for pain
- Experience on average, 1-4 breakthrough pain episodes per day
- Opioid or fentanyl intolerance
- Sleep apnea or active brain metastases with increased intracranial pressure
- COPD (chronic obstructive pulmonary disease); cardiopulmonary disease; heart disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (26)
Cullman Oncology and Hematology
🇺🇸Cullman, Alabama, United States
Advanced Clinical Research Institute
🇺🇸Anaheim, California, United States
Pacific Cancer Medical Center
🇺🇸Anaheim, California, United States
Compassionate Cancer Care Medical Group
🇺🇸Corona, California, United States
Compassionate Cancer Center
🇺🇸Fountain Valley, California, United States
Clinical Trials & Research Associates, Inc.
🇺🇸Montebello, California, United States
San Diego Hospice & Palliative Care
🇺🇸San Diego, California, United States
Pacific Clinical Research
🇺🇸Santa Monica, California, United States
Lovelace Scientific Resources
🇺🇸Miami, Florida, United States
Gulf Coast Pain Specialists
🇺🇸Pensacola, Florida, United States
Scroll for more (16 remaining)Cullman Oncology and Hematology🇺🇸Cullman, Alabama, United States